$ATRC News
Last published 1d ago
- 1d agoATRCSTIFEL 2026 HEALTHCARE CONFERENCE - ATRICURE INCEarnings Call TranscriptsGood afternoon, everyone. I hope everybody had a nice lunch. For those listening, my name is John McCauley. I'm one of the medical technology analysts here at Stifel. It's my pleasure to welcome Atricure to the 2026 Stif
- 1d agoATRCSTIFEL 2026 HEALTHCARE CONFERENCE - ATRICURE INCEarnings Call TranscriptsGood afternoon, everyone. I hope everybody had a nice lunch. For those listening, my name is John McCauley. I'm one of the medical technology analysts here at Stifel. It's my pleasure to welcome Atricure to the 2026 Stif
- 3d agoATRCAtriCure Earnings Call - ATRICURE INCEarnings Call TranscriptsAll righty. Oh, goodness me. That was powerful. Welcome. Thanks, everyone. It's Patrick Wood on the UBS MedTech team. I'd appreciate everyone for joining us. And a big thank you to Angie, CFO of AtroCure, for agreeing to
- 3d agoATRCAtriCure - 1780192 - ATRICURE INCEarnings Call TranscriptsAll righty. Oh, goodness me. That was powerful. Welcome. Thanks, everyone. It's Patrick Wood on the UBS MedTech team. I'd appreciate everyone for joining us. And a big thank you to Angie, CFO of AtroCure, for agreeing to
- 1w agoATRCAtriCure, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoATRCQ3 2026 AtriCure, Inc. Earnings Conference Call - ATRICURE INCEarnings Call TranscriptsGood afternoon, and welcome to Atricure's third quarter 2026 earnings conference call. This call is being recorded for replay purposes, and at this time, all participants are in listen-only mode. We will be facilitating
- 2w agoATRCAtriCure to Participate at Upcoming Investor ConferencesBusiness WireAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the
- 1mo agoATRCAtriCure to Announce Third Quarter 2026 Financial ResultsBusiness WireAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will
- 2mo agoATRCAtriCure to Participate in the 2026 Wells Fargo Health Care ConferenceBusiness WireAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the
- 3mo agoATRC46TH ANNUAL GROWTH CONFERENCE - ATRICURE INCEarnings Call TranscriptsAll right, good morning. Welcome to the Canaccord Genuity Global Growth Conference, 46th annual. My name is Bill Pledonik. I'm one of the senior analysts here on the MedTech team for Canaccord. I'm excited to have the ma
- 3mo agoATRCCG 46TH ANNUAL GROWTH CONFERENCE - ATRICURE INCEarnings Call TranscriptsAll right, good morning. Welcome to the Canaccord Genuity Global Growth Conference, 46th annual. My name is Bill Pledonik. I'm one of the senior analysts here on the MedTech team for Canaccord. I'm excited to have the ma
- 3mo agoATRCAtriCure to Participate at Upcoming Investor ConferencesBusiness WireAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the
- 3mo agoINSPATRCInspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of DirectorsGlobeNewswireMINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea
- 3mo agoATRCAtriCure Reports Second Quarter 2026 Financial ResultsBusiness WireSecond Quarter 2026 worldwide revenue of $153.6 million, an increase of 12.8% year over year Second Quarter 2026 profitability strengthened, with net income of $9.0 million and adjusted EBITDA of $27.3
- 4mo agoATRCAtriCure to Announce Second Quarter 2026 Financial ResultsBusiness WireAtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will
- 5mo agoATRCGoldman Sachs 47th Annual Global Healthcare ConferenceATRICURE INCEarnings Call TranscriptsGood morning, everybody. I'm very pleased to welcome everyone to the last day here of the Goldman Sachs Healthcare Conference. I am very pleased to have the management team here from HECARE, Mike Carroll, Chief Executive
- 5mo agoATRCAtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care ConferenceBusiness WireAtriCure, Inc. ((
- 6mo agoATRC2026 GLOBAL HEALTHCARE CONFERENCEATRICURE INCEarnings Call TranscriptsAll right. Good morning, everyone. My name is Aidan Leahy. I'm on the MedTech team here at Bank of America. Really happy to introduce Atric here. We have CEO Mike Carroll and CFO Angie Wyrick. We're going to do a 30-minu
- 6mo agoATRCQ1 2026 AtriCure, Inc. Earnings Conference CallATRICURE INCEarnings Call TranscriptsGood afternoon and welcome to ATRA Cures first quarter 2026 earnings conference call. This call is being recorded for replay purposes and at this time all participants are in listen-only mode. We will be facilitating a q
- 6mo agoATRCAtriCure Reports First Quarter 2026 Financial ResultsBusiness WireFirst Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA of $17.1 million U.S.
- 6mo agoATRCAtriCure to Participate in the 2026 Bank of America Securities Health Care ConferenceBusiness WireAtriCure, Inc. ((
- 7mo agoATRCAtriCure to Announce First Quarter 2026 Financial ResultsBusiness WireAtriCure, Inc. ((
- 8mo agoATRCAtriCure to Participate in the Citizens Life Sciences ConferenceBusiness WireAtriCure, Inc. ((
- 8mo agoATRCAtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial ResultsBusiness WireFourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide
- 8mo agoATRCQ4 and Full Year 2025 AtriCure, Inc. Earnings Conference CallATRICURE INCEarnings Call TranscriptsGood afternoon and welcome to AtriCure's fourth quarter and full year 2025 earnings conference call. This call is being recorded for replay purposes and at this time all participants are in listen-only mode. We will be f
- 10mo agoATRCCBLLEWHTFLAI Diagnostics: The End of the High-Cost Imaging EraGlobeNewswireVANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]. This systemic
- 11mo agoATRCAtriCure to Participate in the J.P. Morgan 44th Annual Healthcare ConferenceBusiness WireAtriCure, Inc. ((
- 11mo agoATRCAtriCure, Inc. - Appeal, ReversedUS Patent Trial and Appeal Board
- 11mo agoATRCAtriCure Announces the First Patients Treated with Novel Dual Energy PlatformBusiness WireNew technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure's EnCompass® clamp to reduce treatment time for surgical ablation patients AtriCure, Inc. ((
- 11mo agoATRCAtriCure to Participate in the Piper Sandler 37th Annual Healthcare ConferenceBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025Business WireWorldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an
- 1y agoATRCAtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical TrialBusiness WireTrial will evaluate the safety and effectiveness of the AtriCure Isolator® Synergy™ EnCompass® clamp and AtriClip® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset
- 1y agoATRCAtriCure to Participate in Upcoming Investor ConferencesBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following AmputationBusiness WireNew device expands AtriCure's market opportunity in post-operative pain management while addressing a significant unmet clinical need AtriCure, Inc. ((
- 1y agoATRCAtriCure to Participate in the 2025 Wells Fargo Healthcare ConferenceBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure, Inc. (ATRC) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoATRCAtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025Business WireWorldwide revenue of $136.1 million – an increase of 17.1% year over year (16.5% constant currency) Net loss of $6.2 million – an improvement of $1.8 million year over year Adjusted EBITDA of $15.4 million – an
- 1y agoATRCAtriCure to Participate in the Canaccord Genuity 45th Annual Growth ConferenceBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke PreventionBusiness WireLargest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery patients globally without
- 1y agoATRCAtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure Reports First Quarter 2025 Financial ResultsBusiness WireWorldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an
- 1y agoATRCAtriCure Announces First Use of the AtriClip PRO-Mini® DeviceBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure to Announce First Quarter 2025 Financial ResultsBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure to Host Analyst & Investor Day on March 26, 2025Business WireAtriCure, Inc. ((
- 1y agoATRCAtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial ResultsBusiness WireFourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE®+,
- 1y agoATRCAtriCure to Announce Fourth Quarter and Full Year 2024 Financial ResultsBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor DayBusiness WireAtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced
- 1y agoATRCAtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness WireAtriCure, Inc. ((
- 1y agoATRCAtriCure to Participate in the Piper Sandler 36th Annual Healthcare ConferenceBusiness WireAtriCure, Inc. ((
- 2y agoATRCAtriCure to Participate in the Stifel 2024 Healthcare ConferenceBusiness WireAtriCure, Inc. ((